Evonik Shares Receive Bullish 20 Euro Price Target

Evonik shares surge as Goldman Sachs and ODDO BHF raise targets to €20, citing strong pricing power and insider buying confidence ahead of Q1 results.

A notable shift in sentiment is underway among major investment banks regarding Evonik, the Essen-based specialty chemicals group. The company is currently benefiting from robust tailwinds driven by stronger-than-anticipated pricing power and constrained market supply. This operational strength, coupled with significant share purchases by company insiders, provides solid justification for the stock's recent upward trajectory.

Management Confidence Evident in Insider Purchases

Adding a layer of conviction to the fundamental story, members of Evonik's leadership have been active buyers of the stock. Regulatory filings from the end of the first quarter confirm that executives are utilizing the current price level for personal investment. Notable recent transactions include:

• Dr. Claudine Mollenkopf (Executive Board): Purchase at approximately €16.50
• Dr. Cornelius Baur (Supervisory Board): Purchase at approximately €16.29

Market observers frequently interpret such insider activity as a confirmation of internal growth confidence, particularly when it coincides with positive analyst commentary.

Analyst Upgrades Fueled by Pricing Strength and Market Dynamics

The primary driver for the renewed optimism is a series of analyst upgrades. Strategists at both Goldman Sachs and ODDO BHF have simultaneously raised their price targets for Evonik to €20.00. According to Goldman Sachs analyst Georgina Fraser, this reassessment is largely attributable to significant price increases within the Advanced Technologies segment. When combined with favorable currency effects, the adjusted EBITDA for the first quarter could substantially surpass current market expectations.

The equity has already begun to reflect this positive outlook. Since the start of the year, the share price has climbed by a solid 24%, recently trading at €16.54. Beyond direct price hikes, the company is profiting from a favorable supply-demand balance in C4 chemicals, where currently tight supply is supporting margins. Furthermore, the methionine business, a key pillar for feed proteins, is strengthening its competitive position through an improved cost structure.

All eyes will be on Evonik's official first-quarter results, scheduled for release on May 8, 2026. The report will reveal whether the forecasted EBITDA surprise, powered by enhanced pricing power, has been fully realized. For the full 2026 fiscal year, management's guidance remains unchanged, targeting an adjusted EBITDA in the range of €1.7 to €2.0 billion.